A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Inclusion 23

• Minimum age: 60 years
• Study condition: Oncology, Myeloid Leukemia, Acute, Cancer
• Patients
• Age ≥60 years (from date of consent, confirmed on electronic medical records)
• A new diagnosis of AML
• Diagnosis can be based on the International Consensus Classification or World Health Organization
• Myeloid sarcoma is allowed
• AML with central nervous system involvement is allowed
• Cancer-directed treatment has not started
• Treatment to temporarily decrease white blood cells is acceptable; these may include hydroxyurea, leukapheresis, or cytarabine
• Intrathecal chemotherapy is acceptable
• The patient's oncologist has been or will be enrolled on the study
• English or Spanish-speaking
• Patients without a caregiver will still be eligible to participate in the study Exclusion criteria
• A diagnosis of acute promyelocytic leukemia
• Patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits informed consent or compliance with study procedures
• Prior cancer-directed treatment for AML
• Caregivers
• Selected by the patient when asked if there is a "family member, partner, friend or caregiver \[age 18 or older\] with whom you discuss or who can be helpful in healthrelated matters."
• Caregiver may be paid/professional or informal caregiver
• Able to provide informed consent
• Oncologists
• Oncologists caring for patients with AML Exclusion criteria